TTD_Target_ID Target_Name TTD_Drug_ID Drug_Name Drug_Highest_Status Drug_PubchemID Molecular_Formula Molecular_Weight Canonical_SMILES Activity Binder_Type T20251 Voltage-gated potassium channel Kv11.1 D03DIG Codeine Approved 5284371 C18H21NO3 299.4 CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3[C@H](C=C4)O IC50 = 301995.17 nM Non binder T20251 Voltage-gated potassium channel Kv11.1 D03FLC Lamotrigine Approved 3878 C9H7Cl2N5 256.089 C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N IC50 = 229086.77 nM Non binder T20251 Voltage-gated potassium channel Kv11.1 D08CDI Lapatinib Approved 208908 C29H26ClFN4O4S 581.1 CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl IC50 = 630957.34 nM Non binder T20251 Voltage-gated potassium channel Kv11.1 D0AO5H Trimethoprim Approved 5578 C14H18N4O3 290.32 COC1=CC(=CC(=C1OC)OC)CC2=CN=C(N=C2N)N IC50 = 239883.29 nM Non binder T20251 Voltage-gated potassium channel Kv11.1 D0D7KC Alvimopan Approved 5488548 C25H32N2O4 424.5 C[C@H]1CN(CC[C@@]1(C)C2=CC(=CC=C2)O)C[C@H](CC3=CC=CC=C3)C(=O)NCC(=O)O IC50 = 794328.23 nM Non binder T20251 Voltage-gated potassium channel Kv11.1 D0K3QS Everolimus Approved 6442177 C53H83NO14 958.2 C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)OCCO)C)/C)O)OC)C)C)/C)OC IC50 = 501187.23 nM Non binder T20251 Voltage-gated potassium channel Kv11.1 D0L3MP VRX496 Approved 64143 C32H45N3O4S 567.8 CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O IC50 = 501187.23 nM Non binder T20251 Voltage-gated potassium channel Kv11.1 D0O3FG Desvenlafaxine Approved 125017 C16H25NO2 263.37 CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O IC50 = 251188.64 nM Non binder T20251 Voltage-gated potassium channel Kv11.1 D0R1RS Indomethacin Approved 3715 C19H16ClNO4 357.8 CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O IC50 = 301995.17 nM Non binder T20251 Voltage-gated potassium channel Kv11.1 D0T8GD Nicotine Approved 89594 C10H14N2 162.23 CN1CCC[C@H]1C2=CN=CC=C2 IC50 = 244299.74 nM Non binder T20251 Voltage-gated potassium channel Kv11.1 D0T8XB Anagliptin Approved 44513473 C19H25N7O2 383.4 CC1=NN2C=C(C=NC2=C1)C(=O)NCC(C)(C)NCC(=O)N3CCC[C@H]3C#N IC50 > 500000 nM Non binder T20251 Voltage-gated potassium channel Kv11.1 D0X4RN Lidocaine Approved 3676 C14H22N2O 234.34 CCN(CC)CC(=O)NC1=C(C=CC=C1C)C IC50 = 263026.8 nM Non binder T20251 Voltage-gated potassium channel Kv11.1 D0X5ZI Ambrisentan Approved 6918493 C22H22N2O4 378.4 CC1=CC(=NC(=N1)O[C@H](C(=O)O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC)C IC50 = 501187.23 nM Non binder T20251 Voltage-gated potassium channel Kv11.1 B0YX8V 6-Cyano-N-[(1R)-1-[1-ethyl-6-(trifluoromethyl)imidazo[4,5-c]pyridin-2-yl]ethyl]pyridine-3-sulfonamide Investigative 24985395 C17H15F3N6O2S 424.4 CCN1C2=CC(=NC=C2N=C1[C@@H](C)NS(=O)(=O)C3=CN=C(C=C3)C#N)C(F)(F)F IC50 > 200000 nM Non binder T20251 Voltage-gated potassium channel Kv11.1 B15XCF (9S)-9-Amino-9-deoxoerythromycin Investigative 83952 C37H70N2O12 735 CC[C@@H]1[C@@]([C@@H]([C@H]([C@H]([C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)N)C)O)(C)O IC50 = 316227.77 nM Non binder T20251 Voltage-gated potassium channel Kv11.1 B19DRT (3R,4R)-4-Amino-3-(pyrrolidine-1-carbonyl)-1-(quinoxaline-3-carbonyl)pyrrolidin-2-one Investigative 44443420 C18H19N5O3 353.4 C1CCN(C1)C(=O)[C@H]2[C@H](CN(C2=O)C(=O)C3=NC4=CC=CC=C4N=C3)N IC50 > 300000 nM Non binder T20251 Voltage-gated potassium channel Kv11.1 B1QS9R 6-[[[4-[(1R)-1-Amino-2-(7-fluoro-4-methyl-2-oxoquinolin-1-yl)ethyl]cyclohexyl]amino]methyl]-4H-pyrido[3,2-b][1,4]oxazin-3-one Investigative 46206324 C26H30FN5O3 479.5 CC1=CC(=O)N(C2=C1C=CC(=C2)F)C[C@@H](C3CCC(CC3)NCC4=NC5=C(C=C4)OCC(=O)N5)N IC50 > 333000 nM Non binder T20251 Voltage-gated potassium channel Kv11.1 B2XRM5 6-Cyano-N-[(1R)-1-(6-cyclopropyl-1-ethylimidazo[4,5-c]pyridin-2-yl)ethyl]pyridine-3-sulfonamide Investigative 24985745 C19H20N6O2S 396.5 CCN1C2=CC(=NC=C2N=C1[C@@H](C)NS(=O)(=O)C3=CN=C(C=C3)C#N)C4CC4 IC50 > 200000 nM Non binder T20251 Voltage-gated potassium channel Kv11.1 B30XNR 5-(2-(1,4''-Bipiperidin-1''-yl)thiazolo[4,5-b]pyridin-6-yl)pyridin-2-ol Investigative 45482688 C21H25N5OS 395.5 C1CCN(CC1)C2CCN(CC2)C3=NC4=C(S3)C=C(C=N4)C5=CNC(=O)C=C5 IC50 = 323333.33 nM Non binder T20251 Voltage-gated potassium channel Kv11.1 B3W1CG 1-Cyclopropyl-6-fluoro-7-[(8Z)-8-methoxyimino-2,6-diazaspiro[3.4]octan-6-yl]-4-oxo-2,3-dihydro-1,8-naphthyridine-3-carboxylic acid Investigative 53326693 C19H22FN5O4 403.4 CO/N=C/1\\CN(CC12CNC2)C3=C(C=C4C(=O)C(CN(C4=N3)C5CC5)C(=O)O)F IC50 = 218776.16 nM Non binder T20251 Voltage-gated potassium channel Kv11.1 B62CEQ (3R,4R)-4-[(3S)-3-(3-Fluoro-6-methoxyquinolin-4-yl)-3-hydroxypropyl]-1-[3-(1,2-oxazol-5-yl)cyclobutyl]piperidine-3-carboxylic acid Investigative 137660546 C26H30FN3O5 483.5 COC1=CC2=C(C(=CN=C2C=C1)F)[C@H](CC[C@@H]3CCN(C[C@@H]3C(=O)O)C4CC(C4)C5=CC=NO5)O IC50 > 300000 nM Non binder T20251 Voltage-gated potassium channel Kv11.1 B6AWL2 2-[[[4-[(1R)-1-Amino-2-(6-fluoro-7-methoxy-2-oxoquinoxalin-1-yl)ethyl]cyclohexyl]amino]methyl]-8H-pyrimido[5,4-b][1,4]oxazin-7-one Investigative 118720931 C24H28FN7O4 497.5 COC1=C(C=C2C(=C1)N(C(=O)C=N2)C[C@@H](C3CCC(CC3)NCC4=NC=C5C(=N4)NC(=O)CO5)N)F IC50 > 333000 nM Non binder T20251 Voltage-gated potassium channel Kv11.1 B79QBZ (3R)-3-[[4-(2,3-Dihydro-[1,4]dioxino[2,3-c]pyridin-7-ylmethylamino)-2-oxabicyclo[2.2.2]octan-1-yl]methyl]-5-fluoro-3-hydroxy-1,7-diazatricyclo[6.3.1.04,12]dodeca-4(12),5,7,9-tetraen-11-one Investigative 118736667 C26H27FN4O5 494.5 C1CC2(CCC1(CO2)NCC3=CC4=C(C=N3)OCCO4)C[C@@]5(CN6C(=O)C=CC7=NC=C(C5=C76)F)O IC50 = 764000 nM Non binder T20251 Voltage-gated potassium channel Kv11.1 B7RY1G CID 25008765 Investigative 25008765 C25H26N6O4 474.5 C1CN(C[C@H]([C@H]1NCC2=NC3=C(C=C2)OCC(=O)N3)O)CCN4C(=O)C=CC5=C4C=C(C=C5)C#N IC50 = 305000 nM Non binder T20251 Voltage-gated potassium channel Kv11.1 B97HXD 4-[6-(Azetidine-1-carbonyl)-5-fluoropyridin-3-yl]oxy-2-ethyl-N-(5-methylpyrazin-2-yl)indazole-6-carboxamide Investigative 46911124 C24H22FN7O3 475.5 CCN1C=C2C(=CC(=CC2=N1)C(=O)NC3=NC=C(N=C3)C)OC4=CC(=C(N=C4)C(=O)N5CCC5)F IC50 > 300000 nM Non binder T20251 Voltage-gated potassium channel Kv11.1 BB02YS 3-[[4-(3,4-Dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carbonyloxymethyl)piperidin-1-yl]methyl]cyclopentane-1-carboxylic acid Investigative 118712578 C25H32N2O5 440.5 C1CN2C3=CC=CC=C3C(=C2OC1)C(=O)OCC4CCN(CC4)CC5CCC(C5)C(=O)O IC50 = 209000 nM Non binder T20251 Voltage-gated potassium channel Kv11.1 BD2U7Z N-(4-Chlorophenyl)-2-[5-methoxy-3-[(E)-[(4-methylphenyl)sulfonylhydrazinylidene]methyl]indol-1-yl]acetamide Investigative 73349556 C25H23ClN4O4S 511 CC1=CC=C(C=C1)S(=O)(=O)N/N=C/C2=CN(C3=C2C=C(C=C3)OC)CC(=O)NC4=CC=C(C=C4)Cl IC50 = 418350 nM Non binder T20251 Voltage-gated potassium channel Kv11.1 BF12KZ N-Ethyl-2-[3-(trifluoromethyl)phenyl]ethanamine Investigative 53326682 C11H14F3N 217.23 CCNCCC1=CC(=CC=C1)C(F)(F)F IC50 = 537031.8 nM Non binder T20251 Voltage-gated potassium channel Kv11.1 BF1G9R CID 60200128 Investigative 60200128 C25H26N6O4 474.5 C1CN(C[C@@H]([C@@H]1NCC2=NC3=C(C=C2)OCC(=O)N3)O)CCN4C(=O)C=CC5=C4C=C(C=C5)C#N IC50 > 333000 nM Non binder T20251 Voltage-gated potassium channel Kv11.1 BF29IR 2-[[[4-[(1R)-1-Amino-2-(7-methoxy-2-oxoquinoxalin-1-yl)ethyl]cyclohexyl]amino]methyl]-8H-pyrimido[5,4-b][1,4]oxazin-7-one Investigative 46205345 C24H29N7O4 479.5 COC1=CC2=C(C=C1)N=CC(=O)N2C[C@@H](C3CCC(CC3)NCC4=NC=C5C(=N4)NC(=O)CO5)N IC50 > 333000 nM Non binder T20251 Voltage-gated potassium channel Kv11.1 BG8AX4 (2R)-2-[4-[[[(2S)-3-[(3R)-3-Amino-4-(2,4,5-trifluorophenyl)butanoyl]-1,3-thiazolidine-2-carbonyl]amino]methyl]anilino]-3-methylbutanoic acid;hydrochloride Investigative 24860299 C26H32ClF3N4O4S 589.1 CC(C)[C@H](C(=O)O)NC1=CC=C(C=C1)CNC(=O)[C@H]2N(CCS2)C(=O)C[C@@H](CC3=CC(=C(C=C3F)F)F)N.Cl EC50 = 408000 nM Non binder T20251 Voltage-gated potassium channel Kv11.1 BGQ2U5 2-[[2-[(3R)-3-Aminopiperidin-1-yl]-7-bromo-4-oxo-5H-pyrrolo[3,2-d]pyrimidin-3-yl]methyl]benzonitrile Investigative 57385073 C19H19BrN6O 427.3 C1C[C@H](CN(C1)C2=NC3=C(C(=O)N2CC4=CC=CC=C4C#N)NC=C3Br)N IC50 > 300000 nM Non binder T20251 Voltage-gated potassium channel Kv11.1 BHRL26 (3S)-3-[[4-(2,3-Dihydro-[1,4]dioxino[2,3-c]pyridin-7-ylmethylamino)piperidin-1-yl]methyl]-5,10-difluoro-3-hydroxy-1,7-diazatricyclo[6.3.1.04,12]dodeca-4(12),5,7,9-tetraen-11-one Investigative 23634277 C24H25F2N5O4 485.5 C1CN(CCC1NCC2=CC3=C(C=N2)OCCO3)C[C@@]4(CN5C6=C4C(=CN=C6C=C(C5=O)F)F)O IC50 = 289000 nM Non binder T20251 Voltage-gated potassium channel Kv11.1 BJ6NL2 Chembl4283796 Investigative 138964067 C19H23FN4O4S2 454.5 CCN(CC(=O)N1CCC[C@H]1C2=CC(=C(S2)C)C(=O)NC3=NC=C(S3)F)CC(=O)O IC50 > 300000 nM Non binder T20251 Voltage-gated potassium channel Kv11.1 BJH1K2 2-((2R,3S,4R,5R,6S,7R,9R,10R,11S,12S,13R)-2-Ethyl-3,4,9-trihydroxy-10-((2S,3R,4S,6R)-3-hydroxy-4-(isopropyl(methyl)amino)-6-methyltetrahydro-2H-pyran-2-yloxy)-12-((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yloxy)-3,5,7,9,11,13-hexamethyl-14-oxooxacyclotetradecan-6-yloxy)-N-methylacetamide Investigative 45483679 C42H78N2O14 835.1 CC[C@@H]1[C@@]([C@@H]([C@H]([C@H]([C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C(C)C)O)(C)O)C)OCC(=O)NC)C)O)(C)O IC50 = 411000 nM Non binder T20251 Voltage-gated potassium channel Kv11.1 BM0H1N 2-(trans-4-(4-(7-Aminopyrazolo[1,5-a]pyrimidin-6-yl)phenyl)cyclohexyl)acetic acid Investigative 56933229 C20H22N4O2 350.4 C1CC(CCC1CC(=O)O)C2=CC=C(C=C2)C3=C(N4C(=CC=N4)N=C3)N IC50 > 300000 nM Non binder T20251 Voltage-gated potassium channel Kv11.1 BMI7R9 2-[[2-[(3R)-3-Aminopiperidin-1-yl]-6-methyl-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-3-yl]methyl]benzonitrile Investigative 57385070 C20H22N6O 362.4 CC1=CC2=C(N1)N=C(N(C2=O)CC3=CC=CC=C3C#N)N4CCC[C@H](C4)N IC50 > 300000 nM Non binder T20251 Voltage-gated potassium channel Kv11.1 BMV0S2 2-[[2-[(3R)-3-Aminopiperidin-1-yl]-6-bromo-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-3-yl]methyl]benzonitrile Investigative 57385071 C19H19BrN6O 427.3 C1C[C@H](CN(C1)C2=NC3=C(C=C(N3)Br)C(=O)N2CC4=CC=CC=C4C#N)N IC50 > 300000 nM Non binder T20251 Voltage-gated potassium channel Kv11.1 BMWG84 6H-Pyrimido[5,4-b][1,4]oxazin-7(8H)-one, 2-[[[trans-4-[(1R)-1-amino-2-(7-fluoro-2-oxo-1(2H)-quinoxalinyl)ethyl]cyclohexyl]amino]methyl]- Investigative 46206000 C23H26FN7O3 467.5 C1CC(CCC1[C@H](CN2C3=C(C=CC(=C3)F)N=CC2=O)N)NCC4=NC=C5C(=N4)NC(=O)CO5 IC50 > 333000 nM Non binder T20251 Voltage-gated potassium channel Kv11.1 BN8C0R 1-[2-[(3R,4S)-4-(2,3-Dihydro-[1,4]dioxino[2,3-c]pyridin-7-ylmethylamino)-3-fluoropiperidin-1-yl]ethyl]-2-oxoquinoline-7-carbonitrile Investigative 25008769 C25H26FN5O3 463.5 C1CN(C[C@H]([C@H]1NCC2=CC3=C(C=N2)OCCO3)F)CCN4C(=O)C=CC5=C4C=C(C=C5)C#N IC50 > 200000 nM Non binder T20251 Voltage-gated potassium channel Kv11.1 BO8U6X Methyl (4aS,6aR,6bS,8aR,12R,12aS,14aR,14bS)-10-[[4-[[(4S)-4-amino-5-methoxy-5-oxopentanoyl]amino]phenyl]methoxy]-11-cyano-12-hydroxy-2,2,6a,6b,9,9,12a-heptamethyl-14-oxo-3,4,5,6,7,8,8a,12,14a,14b-decahydro-1H-picene-4a-carboxylate Investigative 137647489 C45H61N3O8 772 C[C@@]12CC[C@]3(CCC(C[C@H]3[C@H]1C(=O)C=C4[C@]2(CC[C@@H]5[C@@]4([C@H](C(=C(C5(C)C)OCC6=CC=C(C=C6)NC(=O)CC[C@@H](C(=O)OC)N)C#N)O)C)C)(C)C)C(=O)OC IC50 > 200000 nM Non binder T20251 Voltage-gated potassium channel Kv11.1 BPH2S4 2-(7-(5-(3-Cyano-5-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl)acetic Acid Investigative 44138103 C23H15F3N4O4 468.4 C1CN2C3=C(C=C(C=C3)C4=NOC(=N4)C5=CC(=CC(=C5)C#N)OC(F)(F)F)C=C2C1CC(=O)O IC50 > 400000 nM Non binder T20251 Voltage-gated potassium channel Kv11.1 BQ53FV Ecgonine methyl ester Investigative 104904 C10H17NO3 199.25 CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)O)C(=O)OC IC50 = 416869.38 nM Non binder T20251 Voltage-gated potassium channel Kv11.1 BR0DI5 (1r)-1-[(4-{[(6,7-Dihydro[1,4]dioxino[2,3-C]pyridazin-3-Yl)methyl]amino}piperidin-1-Yl)methyl]-9-Fluoro-1,2-Dihydro-4h-Pyrrolo[3,2,1-Ij]quinolin-4-One Investigative 119057475 C24H26FN5O3 451.5 C1CN(CCC1NCC2=CC3=C(N=N2)OCCO3)C[C@@H]4CN5C(=O)C=CC6=C5C4=C(C=C6)F IC50 = 238000 nM Non binder T20251 Voltage-gated potassium channel Kv11.1 BS7A3X 2-[1-[2-Fluoro-4-[(5R)-2-oxo-5-(triazol-1-ylmethyl)-1,3-oxazolidin-3-yl]phenyl]piperidin-4-ylidene]propanenitrile Investigative 71560403 C20H21FN6O2 396.4 CC(=C1CCN(CC1)C2=C(C=C(C=C2)N3C[C@@H](OC3=O)CN4C=CN=N4)F)C#N IC50 = 213320 nM Non binder T20251 Voltage-gated potassium channel Kv11.1 BTKG52 8-[2-[4-(2,3-Dihydro-[1,4]dioxino[2,3-c]pyridin-7-ylmethylamino)piperidin-1-yl]ethyl]-2-methoxypyrido[2,3-d]pyrimidin-7-one Investigative 56834577 C23H28N6O4 452.5 COC1=NC=C2C=CC(=O)N(C2=N1)CCN3CCC(CC3)NCC4=CC5=C(C=N4)OCCO5 IC50 = 206000 nM Non binder T20251 Voltage-gated potassium channel Kv11.1 BU2J9X Rhynchophylline Investigative 5281408 C22H28N2O4 384.5 CC[C@H]1CN2CC[C@]3([C@@H]2C[C@@H]1/C(=C\\OC)/C(=O)OC)C4=CC=CC=C4NC3=O IC50 = 773000 nM Non binder T20251 Voltage-gated potassium channel Kv11.1 BV3GH5 2-[[2-[(3R)-3-Aminopiperidin-1-yl]-4-oxo-6-pyridin-3-yl-7H-pyrrolo[2,3-d]pyrimidin-3-yl]methyl]benzonitrile Investigative 57385072 C24H23N7O 425.5 C1C[C@H](CN(C1)C2=NC3=C(C=C(N3)C4=CN=CC=C4)C(=O)N2CC5=CC=CC=C5C#N)N IC50 > 300000 nM Non binder T20251 Voltage-gated potassium channel Kv11.1 BVD35W N-{4-[5-(4-Fluoro-phenyl)-3-methyl-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-acetamide Investigative 11639342 C18H17FN4O2S 372.4 CC(=O)NC1=NC=CC(=C1)C2=C(N=C(N2C)S(=O)C)C3=CC=C(C=C3)F IC50 = 213000 nM Non binder T20251 Voltage-gated potassium channel Kv11.1 BVJH09 1-[(2S)-2-Amino-2-[(1r,4S)-4-[({3-oxo-2H,3H,4H-pyrido[3,2-b][1,4]oxazin-6-yl}methyl)amino]cyclohexyl]ethyl]-7-methoxy-1,2-dihydro-1,5-naphthyridin-2-one Investigative 46205341 C25H30N6O4 478.5 COC1=CC2=C(C=CC(=O)N2C[C@@H](C3CCC(CC3)NCC4=NC5=C(C=C4)OCC(=O)N5)N)N=C1 IC50 > 333000 nM Non binder T20251 Voltage-gated potassium channel Kv11.1 BVXU45 6-[[[4-[(1R)-1-Amino-2-(7-methoxy-2-oxoquinoxalin-1-yl)ethyl]cyclohexyl]amino]methyl]-4H-pyrido[3,2-b][1,4]oxazin-3-one Investigative 46205343 C25H30N6O4 478.5 COC1=CC2=C(C=C1)N=CC(=O)N2C[C@@H](C3CCC(CC3)NCC4=NC5=C(C=C4)OCC(=O)N5)N IC50 > 333000 nM Non binder T20251 Voltage-gated potassium channel Kv11.1 BW7NM9 6-[[[1-[2-(2-Oxo-7-pyrimidin-5-yloxy-1,8-naphthyridin-1-yl)ethyl]piperidin-4-yl]amino]methyl]-4H-pyrido[3,2-b][1,4]oxazin-3-one Investigative 122187097 C27H28N8O4 528.6 C1CN(CCC1NCC2=NC3=C(C=C2)OCC(=O)N3)CCN4C(=O)C=CC5=C4N=C(C=C5)OC6=CN=CN=C6 IC50 > 224000 nM Non binder T20251 Voltage-gated potassium channel Kv11.1 BW8P3I 2-[[[4-[(1R)-1-Amino-2-(7-fluoro-4-methyl-2-oxoquinolin-1-yl)ethyl]cyclohexyl]amino]methyl]-8H-pyrimido[5,4-b][1,4]oxazin-7-one Investigative 118720930 C25H29FN6O3 480.5 CC1=CC(=O)N(C2=C1C=CC(=C2)F)C[C@@H](C3CCC(CC3)NCC4=NC=C5C(=N4)NC(=O)CO5)N IC50 > 333000 nM Non binder T20251 Voltage-gated potassium channel Kv11.1 BX4F3B (S)-4-((4-(((2,3-Dihydro-[1,4]dioxino[2,3-C]pyridin-7-Yl)methyl)amino)piperidin-1-Yl)methyl)-3-Fluoro-4-Hydroxy-4h-Pyrrolo[3,2,1-De][1,5]naphthyridin-7(5h)-One Investigative 23633343 C24H26FN5O4 467.5 C1CN(CCC1NCC2=CC3=C(C=N2)OCCO3)C[C@@]4(CN5C(=O)C=CC6=NC=C(C4=C65)F)O IC50 = 239000 nM Non binder T20251 Voltage-gated potassium channel Kv11.1 BYIR87 4-[[3-[4-(Pyrrolidin-1-ylmethyl)phenyl]cyclobutyl]methyl]morpholine Investigative 11313056 C20H30N2O 314.5 C1CCN(C1)CC2=CC=C(C=C2)C3CC(C3)CN4CCOCC4 IC50 = 300000 nM Non binder T20251 Voltage-gated potassium channel Kv11.1 D02BPT [3H]nicotine Investigative 942 C10H14N2 162.23 CN1CCCC1C2=CN=CC=C2 IC50 = 245470.89 nM Non binder T20251 Voltage-gated potassium channel Kv11.1 D03WYU CDDO-Me Investigative 400769 C32H43NO4 505.7 C[C@@]12CC[C@]3(CCC(C[C@H]3[C@H]1C(=O)C=C4[C@]2(CC[C@@H]5[C@@]4(C=C(C(=O)C5(C)C)C#N)C)C)(C)C)C(=O)OC IC50 > 200000 nM Non binder